RxDoctor Payments Data

Janet Wieselthier, MD

Dermatopathology · Lyndhurst, OHNPI 1639174386

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.6% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 35.2% of the total.

$3,006in general payments, 2019–2025

Across 105 payments — averaging $28.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$761
  • Galderma Laboratories, L.p.$381
  • Lilly USA, LLC$310
  • E.r. Squibb & Sons, L.L.C.$210
  • Johnson & Johnson$121
  • plus $166 from 3 others
$21,565in research payments, 2019–2025

Across 8 payments — averaging $2695.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$22K

What the payments were for

  • Speaking & faculty fees$1505%
  • Food & beverage$2,75592%
  • Education$1013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,006 in reported general payments places this provider in the 70th percentile of 25 dermatopathology providers in Ohio.

See all dermatopathology providers in Ohio

Medicare billing

Part B allowed, 2024
$118,698
Medicare patients
418
Services billed
2,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab18$66,813
Fluocinonide63$2,432
Metronidazole17$2,025
Clobetasol Propionate33$1,348
Triamcinolone Acetonide182$1,281
Fluorouracil15$1,236
Betamethasone Dipropionate22$811
Desonide17$576
Ketoconazole26$479
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc20$418
MethotrexateMethotrexate Sodium18$406
Econazole Nitrate16$361
Ciclopirox16$318
Ammonium Lactate17$301
Doxycycline Hyclate27$298

Paid to pharmacies, not to this prescriber.

Other dermatopathology in Lyndhurst

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →